(3R,4R)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate | 1214272-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3R,4R)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate
• 英文别名: tert-butyl (3R,4R)-3-azido-4-hydroxypyrrolidine-1-carboxylate；1-Pyrrolidinecarboxylic acid, 3-azido-4-hydroxy-, 1,1-dimethylethyl ester, (3R,4R)-rel-
• CAS: 1214272-52-2
• 化学式: C₉H₁₆N₄O₃
• 分子量: 228.251
• InChiKey: CSWBTQKOSPXYIE-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3R,4R)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 在 甲醇 、 水 、 三乙胺 、 三苯基膦 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 (3R,4S)-3-氨基-4-羟基吡咯烷-1-羧酸叔丁酯
  参考文献：
  名称：

  Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core

  摘要：

  New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated. Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (similar to 2 to 50 nM), MMP-13 (similar to 2 to 50 nM), and MMP-14 (similar to 4 to 60 nM). Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, similar to 850 to >50 000 nM; MMP-7, similar to 4000 to >25 000 nM). Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)-stereochemistry was optimal for all of the MMPs tested. However, in our newest compounds an interesting shift of preference to the trans form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility. We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.

  DOI：

  10.1021/jm400529f
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 lipase Amano AK-20 甲醇 、 sodium azide 、 氯化铵 、 间氯过氧苯甲酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲基叔丁基醚 、 水 为溶剂， 反应 72.0h， 生成 (3R,4R)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate
  参考文献：
  名称：

  Substituted Heterocyclic Mercaptosulfonamide Metalloprotease Inhibitors

  摘要：

  本发明一般涉及取代的杂环巯基磺酰胺化合物、前体及其衍生物，以及制备这些化合物的方法和包含这些化合物的药物组合物。这些化合物被设计为强效的选择性基质金属蛋白酶（MMPs）抑制剂，包括例如明胶酶、胶原酶、基质溶素、金属弹性蛋白酶、基质溶素和膜型1基质金属蛋白酶。这些抑制剂可用于控制生理和病理过程以及疾病状况，在这些过程中，MMPs被认为发挥着重要作用。

  公开号：

  US20110144179A1

文献信息

• PURINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：US20150141402A1

  公开（公告）日：2015-05-21

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药用盐，其中Q、G、环A、环B、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24和m在此定义。这些新颖的嘌呤衍生物在治疗哺乳动物中的异常细胞生长，如癌症方面具有用途。另外，还涉及含有这些化合物的药物组合物，以及在治疗哺乳动物中的异常细胞生长方面使用这些化合物和组合物的方法。
• [EN] ERK INHIBITORS<br/>[FR] INHIBITEURS D'ERK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100050A1

  公开（公告）日：2016-06-23

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

  本发明提供了一种化合物(I)或其药学上可接受的盐、酯和前药，这些化合物是ERK2抑制剂。该发明还提供了一种包括至少一种化合物(I)和药学上可接受的载体的有效量的药物组合物。该发明还提供了一种包括至少一种化合物(I)的有效量和至少一种其他药学活性成分的有效量（例如，化疗药物等）以及药学上可接受的载体的药物组合物。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
  申请人：——

  公开号：US20020156018A1

  公开（公告）日：2002-10-24

  The present invention relates to compounds and pharmaceutical compositions which inhibit proteases, such as cysteine proteases. In particular, the present invention relates to compounds and pharmaceutical compositions which inhibit cysteine proteases of the papain superfamily. The compounds and pharmaceutical compositions of the present invention are useful for treating diseases, particularly parasitic diseases, which are mediated by such proteases. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.

  本发明涉及抑制蛋白酶的化合物和药物组合物，尤其是抑制木瓜蛋白酶超家族中的半胱氨酸蛋白酶的化合物和药物组合物。本发明的化合物和药物组合物可用于治疗由这类蛋白酶介导的疾病，尤其是寄生虫疾病。特别是，本发明涉及通过抑制疟疾中的半胱氨酸蛋白酶falcipain来治疗疟疾的方法。
• [EN] NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINOPYRIDINE PRÉSENTANT UNE ACTION INHIBITRICE SÉLECTIVE DE L'AURORA A
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010111050A1

  公开（公告）日：2010-09-30

  The present invention relates to a compound of Formula (I): wherein: R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R10; R5 is H, hydroxy, C1-2 alkyl, or OCH3; and R10 is F or Cl, or a pharmaceutically acceptable salt or ester thereof.

  本发明涉及一种化合物，其化学式为（I）：其中：R1为H或C1-2烷基；R2为H或C1-3烷基；R3和R4分别独立地为H或C1-2烷基，其中烷基可能被选自R10的一个到三个相同或不同的取代基取代；R5为H、羟基、C1-2烷基或OCH3；R10为F或Cl，或其药学上可接受的盐或酯。